DNA aptamer-based detection of prostate cancer

Chemical Papers

Volumn 69, Issue 1, 2015, Pages 77-89

  Jolly, Pawan ^a   Formisano, Nello ^a   Estrela, Pedro ^a  

^a University of Bath   (United Kingdom)

Author keywords

biosensor; DNA aptamer; electrochemical detection; prostate cancer; prostate specific antigen; surface chemistry

Indexed keywords

EID: 84916918984     PISSN: 03666352     EISSN: 13369075     Source Type: Journal    
DOI: 10.1515/chempap-2015-0025     Document Type: Review

References (104)

1. Acevedo, B., Perera, Y., Ruiz, M., Rojas, G., Bení tez, J., Ayala, M., & Gavilondo, J. (2002). Development and validation of a quantitative ELISA for the measurement of PSA concentration. Clinica Chimica Acta, 317, 55-63. DOI: 10.1016/s0009-8981(01)00749-5.
2. Albrecht, S., Brandl, H., Steinke, M., & Freidt, T. (1994). Chemiluminescent enzyme immunoassay of prostate-specific antigen based on indoxyl phosphate substrate. Clinical Chemistry, 40, 1970-1971.
3. Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., Weissfeld, J. L., Yokochi, L. A., O'Brien, B., Cl app, J. D., Rathmell, J. M., Riley, T. L., Hayes, R. B., Kramer, B. S., Izmirlian, G., Miller, A. B., Pinsky, P. F., Prorok, P. C., Gohagan, J. K., & Berg, C. D. (2009). Mortality results from a randomized prostate-cancer screening t rial. New England Journal of Medicine, 360, 1310-1319. DOI: 10.1056/nejmoa0810696.
4. Arya, S. K., & Bhansali, S. (2012). Anti-prostate specific antigen (anti-PSA) modified interdigitated microelectrode-based impedimetric biosensor for PSA detection. Biosensors Journal, 1, H110601. DOI: 10.4303/bj/h110601.
5. Aus, G., Ahlgren, G., Bergdahl, S., & Hugosson, J. (1996). Infection after transrectal core bi opsies of the prostate. British Journal of Urology, 77, 851-855. DOI: 10.1046/j.1464-410x.1996.01014.x.
6. Balducci, L., Pow-Sang, J., Friedland, J., & Diaz, J. I. (1997). Prostate cancer. Clinics in Geriatric Medicine, 13, 283-306.
7. Balk, S. P., Ko, Y. J., & Bubley, G. J. (2003). Biology of prostate-specific antigen. Journal of Clinical Oncology, 21, 383-391. DOI: 10.1200/jco.2003.02.083.
8. Basler, J. W., & Thompson, I. M. (1998). Lest we abandon digital rectal examination as a screening test for prostate cancer. Journal of the National Cancer Institute, 90, 1761-1763. DOI : 10.1093/jnci/90.23.1761.
9. Bertok, T., Klukova, L., Sediva, A., Kasák, P., Semak, V., Micusik, M., Omastova, M., Chovanová, L., Vl?ek, M., Imrich, R., Vikartovska, A., & Tkac, J. (2013). Ultrasensit ive impedimetric lectin biosensors with efficient antifouling properties applied in glycoprofiling of human serum samples. Analytical Chemistry, 85, 7324-7332. DOI: 10.1021/ac401281t.
10. Besselink, G. A. J., Kooyman, R. P. H., van Os, P. J. H. J., Engbers, G. H. M., & Schasfoort, R. B. M. (2004, Signal amplification on planar and gel-type sensor surfaces in surface plasmon resonance-based detection of prostatespecific antigen. Anal ytical Biochemistry, 333, 165-173. DOI: 10.1016/j.ab.2004.05.009.
11. Bostwick, D. G. (1989). The pathology of early prostate cancer. CA: A Cancer Journal for Clinicians, 39, 376-393. DOI: 10.3322/canjclin.39.6.376.
12. Campuzano, S., Pedrero, M., Montemayor, C., Fatás, E., & Pingarró n, J. M. (2006). Characterization of alkanethiol-selfassembled monolayers-modified gold electrodes by electrochemical impedanc e spectroscopy. Journal of Electroanalytical Chemistry, 586, 112-121. DOI: 10.1016/j.jelechem.2005. 09.007.
13. Cao C.,Sim S.J., 2007, Double-enhancement strategy: a practical approach to a femto-molar level detection of prostate specific antigen-?1-antichymotrypsin (PSA/ACT complex) for SPR immunosensing, Journal of Microbiolog y and Biotechnology, 17, 1031-1035.
14. Carter, H. B., Pearson, J. D.,Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L., & Walsh, P. C. (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA: The Journal of the American Medical Association, 267, 2215-2220. DOI: 10.1001/jama.267.16.2215.
15. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991). Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England Journal of Medicine, 324, 1 156-1161. DOI: 10.1056/nejm199104253241702.
16. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N. P., Parson, R. E., Gasior, G. H., Loveland, K. G., & Southwick, P. C. (1998). Use of the percentage of free prostatespecific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective mult icenter clinical trial. Journal of the American Medical Association, 279, 1542-1547. DOI: 10.1001/jama.279.19.1542.
17. Chen, Z. G., Lei, Y. L., Chen, X., Wang, Z., & Liu, J. B. (2012). An aptamer b ased resonance light scattering assay of prostate specific antigen. Biosensors and Bioelectronics, 36, 35-40. DOI: 10.1016/j.bios.2012.03.041.
18. Chikkaveeraiah, B. V., Mani, V., Patel, V., Gutkind, J. S., & Rusling, J. F. (2011). Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum. Biosensors and Bioelectronics, 26, 4477-4483. DOI: 10.1016/j.bios.2011.05.005.
19. Chiriaco, M. S., Primiceri, E., Montanaro, A., de Feo, F., Leone, L., Rinaldi, R., & Maruccio, G. (2013). On-chip screening for prostate cancer: An EIS microfluidic platform for contemporary detection of free and total PSA. The Analyst, 138 , 5404-5410. DOI: 10.1039/c3an00911d.
20. Cho, E. J., Lee, J.W., & Ellington, A. D. (2009). Applications of aptamers as sensors. Annual Review of Analytical Chemistry, 2, 241-264. DOI: 10.11 46/annurev.anchem.1.031207.112851.
21. Chornokur, G., Arya, S. K., Phelan, C., Tanner, R., & Bhansali, S. (2011). Impedance-based miniaturized biosensor for ultrasensitive and fast prostate-specific antigen detection. Journal of Sensors, 2011, 983752. DOI: 10.1155/2011/983752.
22. Chou, E., & Simons, J. W. (1997). The molecular biology of prostate cancer morbidity and mortality: Accelerated death from ejaculate poisoning ? Urologic Oncology: Seminars and Original Investigations, 3, 79-84. DOI: 10.1016/s1078-1439(97)00041-0.
23. Christensson, A. S., Bj ork, T., Nilsson, O., Dahlén, U., Matikainen, M. T., Cockett, A. T., A brahamsson, P. A., & Lilja, H. (1993). Serum prostate specific antigen complexed to ?-1-antichymotrypsin as an indicator of prostate cancer. Journal of Urology, 150, 100-105.
24. Clark, S. L., & Remcho, V. T. (2002). Aptamers as analytical reagents. Electrophoresis, 23, 1335-1340. DOI: 10.1002/1522-2683(200205)23:93.0.co;2-e.
25. D'Amico, A. V., Chen, M. H., Roehl, K. A., & Ca talona, W. J. (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New England Journal of Medicine, 351, 125-135. DOI: 10.1056/nejmoa032975.
26. D'Amico, A. V., Renshaw, A. A., Sussman, B., & Chen, M. H. (2005). Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. Journal of the American Medical Association, 294, 440 -447. DOI: 10.1001/jama.294.4.440.
27. Feneley, M. R., Jan, H., Granowska, M., Mather, S. J., Ellison, D., Glass, J., Coptcoat, M., Kirby, R. S., Ogden, C., Oliver, R. T. D., Badenoch, D. F., Chinegwundoh, F. I., Nargund, V. H., Paris , A. M. I., & Britton, K. E. (2000). Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer and Prostatic Diseases, 3, 47-52. DOI: 10.1038/sj.pcan.4500390.
28. Feng, K. J., Sun, C. H., Kang, Y., Chen, J. W., Jiang, J. H., Shen, G. L., & Yu, R. Q. (2008). Label-free electrochemical detection of nanomolar adenosine based on target-induced aptamer displacement. Electrochemistry Comm unications, 10, 531-535. DOI: 10.1016/j.elecom.2008.01.024.
29. Fernández-Sá nchez, C., McNeil, C. J., Rawson, K., & Nilsson, O. (2004). Disposable noncompetitive immunosensor for free and total prostate- specific antigen based on capacitance measurement. Analytical Chemistry, 76, 5649-5656. DOI: 10.1021/ac0494937.
30. Formisano, N., Jolly, P., Cromhout, M., Fogel, R., Limson, J. L., & Estrela, P. (2014). Optimisation of an electrochemical impedance spectroscopy aptasensor by exploiting quartz crystal microbalance with dissipation signals. Sensors and Actuators B, submitted.
31. Ghosh, A., & Heston, W. D. W. (2004). T umor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal of Cellular Biochemistry, 91, 528-539. DOI: 10.1002/jcb.10661.
32. Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000). Cancer statistics, 2000. CA: A Cancer Journal for Clinicians, 50, 7-33. DOI: 10.3322/canjclin.50.1.7.
33. Grossklaus, D. J., Smith, J. A., Shappell, S. B., Coffey, C. S., Chang, S. S., & Cookson, M. S. (2002). The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy spec imen among men with an elevated PSA. Urologic Oncology: Semina rs and Original Investigations, 7, 195-198. DOI: 10.1016/s1078-1439(02)00190-4.
34. Healy D.A.,Hayes C.J.,Leonard P.,Mc Kenna L.,O'Kennedy R., 2007, Biosensor developments: Application t o prostate-specific antigen detection, Trends in Biotechnology, 25, 125-131,doi10.1016/j.tibtech.2007.01.004.
35. Hermann, T., & Patel, D. J. (2000). Adaptive recognition by nucleic acid aptamers. Science, 287, 820-825. DOI: 10.1126/science. 287.5454.820.
36. Herne, T. M., & Tarlov, M. J. (1997). Characterization of DNA probes immobilized on gold surfaces. Journal of the American Chemical Socie ty, 119, 8916-8920. DOI: 10.1021/ja9719586.
37. Hianik, T., & Wang, J. (2009). Electrochemical aptasensors-recent achievements and perspectives. Electroanalysis, 21, 1223-1235. DOI: 10.1002/elan.200904566.
38. Hoffman, R. M. (2011). Screening for prostate cancer. New England Journal of Medicine, 365, 2013-2019. DOI: 10.1056/nejmcp1103642.
39. Huang, L., Reekmans, G., Saerens, D., Friedt, J. M., Frederix, F., Francis, L., Muyldermans, S., Campitelli, A., & Van Hoof, C. (2005). Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enha nced sandwich assays. Biosensors and Bioelectronics, 21, 483-490. DOI: 10.1016/j.bios.2004.11.016.
40. Huang, Y. W., Wu, C. S., Chuang, C. K., Pang, S. T., Pan, T. M., Yang, Y. S., & Ko, F. H. (2013). Real-time and label-free detection of the prostate-specific antigen in human serum by a polycrystalline silicon nanowire field-effect transistor biosensor. Analytical Chemistry, 85, 7912-7918. DOI: 10.1021/ac401610s.
41. Ikebukuro, K., Kiyohara, C., & Sode, K. (2005). Novel electrochemical sensor system for protein using the aptamers in sandwich manner. Biosensors and Bioelectronics, 20, 2168-2172. DOI: 10.1016/j.bios.200 4.09.002.
42. Iliuk, A. B., Hu, L. H., & Tao, W. A. (2011). Aptamer in bioanalytical applications. Analytical Chemistry, 83, 4440-4452. DOI: 10.1021/ac201057w.
43. Irani, J., Fournier, F., B on, D., Gremmo, E., Dore, B., & Aubert, J. (1997). Patient tolerance of transrectal ultrasoundguided biopsy of the prostate. British Journal of Urology, 79, 608-610. DOI: 10.1046/j.1464-410x.1997.00120.x.
44. Jeong, S., Han, S. R., Lee, Y. J., & Lee, S. W. (2010). Selection of RNA aptamers specific to active prostate-specific antigen. Biotechnology Letters, 32, 379-385. DOI: 10.1007/s10529-009-0168-1.
45. Jiang, Z., Fanger, G. R.,Woda, B. A., Banner, B. F., Algate, P., Dresser, K., Xu, J. C., & Chu, P. G. G. (2003). Expression of ?-methylacyl-CoA racemase (p504s) in various malignant neoplasms and normal tissues : A study of 761 cases. Human Pathology, 34, 792-796. DOI: 10.1016/s0046-8177(03)00268-5.
46. Jolly, P., Formisano, N., Tk á?, J., Kasák, P., Frost, C. G., & Estrela, P. (2014). Label-free impedimet ric prostate cancer aptasensor with antifouling surface chemistry. Analytical Chemistry, submitted.
47. Keighley, S. D., Li, P., Estrela, P., & Migliorato, P. (2008a ). Optimization of DNA immobilization on gold electrod es for label-free detection by electrochemical impedance spectroscopy. Biosensors and Bioelectronics, 23, 1291-1297. DOI: 10.1016/j.bios.2007.11.012.
48. Keighley, S. D., Estrela, P., Li, P., & Migliorato, P. (2008b ). Optimization of label-free DNA detection with electrochemical impedance spectroscopy using PNA probes. Biosensors and Bioelectronics, 24, 906-911. DOI: 10.1016/j.bios.2008.07.041.
49. Kirk, D. (199 7). MRC study: When to commence treatment in advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 1, 11-15.
50. Kufe, D. W., Pollock, R. E., Weichselbaum, R. R., Bast, R. C., Gansler, T. S., Holland, J. F., & Frei, E. (2003). Cancer medicine (6th ed.). Hamilton, ON, Canada: BC Decker.
51. Lee, J. W., Sim, S. J., Cho, S. M., & Lee, J. (2005). Characterization of a self-assembled monol ayer of thiol on a gold surface and the fabrication of a biosensor chip based on surface plasmon resonance for detecting anti-GAD antibody. Biosensors and Bioelectronics, 20, 1422-1427. DOI: 10.1016/j.bios.2004.04.017.
52. Li, C., Curreli, M., Lin, H., Lei, B., Ishikawa, F. N., Datar, R., Cote, R. J., Thompson, M. E., & Zhou, C. W. (2005). Complementary detection of prostate-specific antigen using In2O3 nanowires and carbon nano tubes. Journal of the American Chemical Society, 127, 12484-12485. DOI: 10.1021/ja053761g.
53. Lilja, H., Oldbring, J., Rannevik, G., & Laurell, C. B. (1987). Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. Journal of Clinical Investigation, 80, 281-285. DOI: 10.1172/jci113070.
54. Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate specific antigen and prostate cancer: Prediction, detection and monitoring. Nature Reviews Cancer, 8, 268-278. DOI: 10.1038/nrc2351.
55. Lim, Y. C., Kouzani, A. Z., & Duan, W. (2009). Aptasensors design considerations. In Z. H. Cai, Z. H. Li, Z. Kang, & Y. Liu (Eds.), Computational intelligence and intelligent systems (pp. 118-127). Berlin, Germ any: Springer. DOI: 10.1007/978-3-642-04962-0 14.
56. Lin J.H.,Ju H.X., 2005. Electrochemical and chemiluminescent immunosensors for tumor markers, Biosensors and Bioelectronics, 20, 1461-1470,doi 10.1016/j.bios.2004.05. 008.
57. Liu, B., Lu, L. S., Hua, E. H., Jiang, S. T., & Xie, G. M. (2012). Detection of the human prostate-specific antigen using an aptasensor with gold nanoparticles encapsula ted by graphitized mesoporous carbon. Microchimica Acta, 178, 163-170. DOI: 10.1007/s00604-012-0822-5.
58. Liu, J., Lu, C. Y., Zhou, H., Xu, J. J., Wang, Z. H., & Chen, H. Y. (2013). A dual-function al electrochemical biosensor for the detection of prostate specific antigen and telomerase activity. Chemical Communications, 49, 6602-6604. DOI: 10.1039/c3cc43532f.
59. Loeb, S., & Catalona, W. J. (2007). Prostate-specific antigen in clinical practice. Cancer Letters, 249, 30-39. DOI: 10.1016/j.canlet.2006.12.022.
60. Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R., Rosario, D. J. , Scattoni, V., & Lotan, Y. (2013). Systematic review of complications of prostate biopsy. European Urology, 64, 876-892. DOI: 10.1016/j.eururo.2013.05.049.
61. Love, J. C., Estroff, L. A., Kriebel, J. K., Nuzzo, R. G., &Whitesides, G. M. (2005). Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chemical Reviews, 105, 1103-1170. DOI: 10.1021/cr0300789.
62. Lovgren, J., Valtonen-André , C., Marsal, K., Liua, H., & Lundwall, A. (1999). Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. Journal of Andrology, 20, 348-355. DOI: 10.1002/j.1939-4640.1999.tb02528.x.
63. Lupold, S. E., Hicke, B. J., Lin, Y., & Coffey, D. S. (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research, 62, 4029-4033.
64. Madu, C. O., & Lu, Y. (2010). Novel diagnostic biomarkers for prostate cancer. Journal of Cancer, 1, 150-177. DOI: 10.7150/jca.1.150.
65. Mairal, T., Ozalp, V. C., Sánchez, P. L., Mir, M., Katakis, I., & O'Sullivan, C. K. (2008). Aptamers: Molecular tools for analytical applications. Analytical and Bioanalytical Chemistry, 390, 98 9-1007. DOI: 10.1007/s00216-007-1346-4.
66. Mani, V., Chikkaveeraiah, B. V., Patel, V., Gutkind, J. S., & Rusling, J. F. (2009). Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification. ACS Nano, 3, 585-594. DOI: 10.1021/nn800863w.
67. Melichar, B. (2012). Tumor biomarkers: PSA and beyond. Clinical Chemistry and Laboratory Medicine, 50, 1865- 1869. DOI: 10.1515/cclm-2012-0631.
68. Mikolajczyk, S. D., Marker, K. M., Millar, L. S., Kumar, A., Saedi,M. S., Payne, J. K.,Evans, C. L., Gasoir,C. L., Linton, H. J., Carpenter, P., & Rittenhouse, H. G. (2001). A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Research, 61, 6958-6963.
69. Mikolajczyk, S. D., Catalona, W. J., Evans, C. L., Linton, H. J., Millar, L. S., Marker, K. M., Katir, D., Amirkhan, A., & Rittenhouse, H. G. (2004). Proenzyme forms of prostate-specific antigen in seru m improve the detection of prostate cancer. Clinical Chemistry, 50, 1017-1025. DOI: 10.1373/clinchem.2003.026823.
70. Min, K., Song, K. M., Cho, M., Chun, Y. S., Shim, Y. B., Ku, J. K., & Ban, C . (2010). Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe. Chemical Communications, 46, 5566-5568. DOI: 10.1039/c002524k.
71. Moyer, V. A. (2012). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 157, 120-134. DOI: 10.7326/0003-4819-157-2-201207170-00459.
72. Numnuam, A., Chumbimuni-To rres, K. Y., Xiang, Y., Bash, R., Thavarungkul, P., Kanatharana, P., Pretsch, E., Wang, J., & Bakker, E. (2008). Aptamer-based potentiometric measurements of proteins using ion-selective microelectrodes. Analy tical Chemistry, 80, 707-712. DOI: 10.1021/ac701910r.
73. Ohori, M., Dunn, J. K., & Scardino, P. T. (1995). Is prostatespecific antigen density more useful than prostate-specific antigen levels in the diagno sis of prostate-cancer? Urology, 46, 666-671. DOI: 10.1016/s0090-4295(99)80298-2.
74. Okuno, J., Maehashi, K., Kerman, K., Takamura, Y., Matsumoto, K., & Tamiya, E. (2007). Label-free immunosens or for prostate-specific antigen based on single-walled carbon nanotube array-modified microelectrodes. Biosensors and Bioelectronics, 22, 2377-2381. DOI: 10.1016/j.bios.2006.09. 038.
75. Panini, N. V., Messina, G. A., Salinas, E., Ferná ndez, H., & Raba, J. (2008). Integrated microfluidic systems with an immunosensor modified with carbon nanotubes for detection of prostate specific antigen (PSA) in human serum samples. Biosensors and Bioel ectronics, 23, 1145-1151. DOI: 10.1016/j.bios.2007.11.003.
76. Pinsky, P. F., Andriole, G., Crawford, E. D., Chia, D., Kramer, B. S., Grubb, R., Greenlee, R., & Gohagan, J. K. (2007). Pro state-specific antigen velocity and prostate cancer gleason grade and stage. Cancer, 109, 1689-1695. DOI: 10.1002/cncr.22558.
77. Pircher A.,Hilbe W.,Heidegger I.,Drevs J.,Tichelli A.,Medinger M. , 2011, Biomarkers in tumor angiogenesis and anti-angiogenic therapy, International Journal of Molecular Sciences, 12, 7077-7099,doi 10.3390/ijms12107077.
78. Putzbach, W., & Ronkainen, N. J. (2013). Immobilization techniques in the fabrication of nanomaterial-based electrochemical biosensors: A review. Sensors, 13, 4811-4840. DOI: 10.3390/s130404811.
79. Rodriguez, M. C., Kawde, A. N., & Wang, J. ( 2005). Aptamer biosensor for label-free impedance spectroscopy detection of proteins based on recognition-induced switching of the surface charge. Chemical Communications, 34, 4267-4269. DOI: 10.1039/b506571b.
80. Ros s, R. K., Pike, M. C., Coetzee, G. A., Reichardt, J. K. V., Yu, M. C., Feigelson, H., Stanczyk, F. Z., Kolonel, L. N., & Henderson, B. E. (1998). Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Research, 58, 4497-4504.
81. Rubin, M. A., Zhou, M., Dhanasekaran, S. M., Varambally, S., Barrette, T. R., Sanda, M. G., Pienta, K. J., Ghosh, D., & Chinnaiyan, A. M. (2002). ?-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA: Journal of the American Medical Association, 287, 1662-1670. DOI: 10.1001/jama.287.13.1662.
82. Sardesai, N. P., Barron, J. C., & Rusling, J. F. (2011). Carbon nanotube microwell array for sensitive electrochemiluminescent detection of cancer biomarker proteins. Analytical Chemistry, 83, 6698-6703. DOI: 10.1021/ac201292q.
83. Sarkar, P., Pal, P. S., Ghosh, D., Setford, S. J., & Tothill, I. E. (2002). Amperometric biosensors for detection of the prostate cancer marker (PSA). International Journal of Pharmaceutics, 238, 1-9. DOI: 10.1016/s0378-5173(02)00015-7.
84. Savory, N., Abe, K., Sode, K., & Ikebukuro, K. (2010). Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing. Biosensors and Bioelectronics, 26, 1386-1391. DOI: 10.1016/j.bios.2010.07.057.
85. Seto, Y., Iba, T., & Abe, K. (2001). Development of ultra-high sensitivity bioluminescent enzyme immunoassay for prostatespecific antigen (PSA) using firefly luciferase. Lumine scence, 16, 285-290. DOI: 10.1002/bio.654.
86. Song, S. P., Wang, L. H., Li, J., Zhao, J. L., & Fan, C. H. (2008). Aptamer-based biosensors. TrAC Trends in Analytical Chemistry, 27, 108-117. DOI: 10.1016/j.trac.2007.12.004.
87. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New England Journal of Medicine, 317, 909-916. DOI: 10.1056/nejm198710083171501.
88. Stanford, J. L., Stephenson, R. A., Coyle, L. M., Cerhan, J., Correa, R., Eley, J. W., Gilliland, F., Hankey, B., Kolonel, L. N., Kosary, C., Ross, R., Severson, R., & West, D. (1999). Prostate cancer trends, 1973-1995. Bethesda, MD, USA: SEER Program, National Cancer Institute.
89. Stephan, C., Le in, M., Jung, K., Schnorr, D., & Loening, S. A. (1997). The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Ca ncer, 79, 104-109. DOI: 10.1002/(sici)1097-0142(19970101)79:13.0.co;2-8.
90. Syed, M. A., & Pervaiz, S. (2010). Advances in aptamers. Oligonucleotides, 20, 215-224. DOI: 10.1089/oli.2010.0234.
91. Takayama, T. K., Fujikawa, K., & Davie, E. W. (1997). Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. Journal of Biological Chemi stry, 272, 21582-21588. DOI: 10.1074/jbc.272.34.21582.
92. Tombelli, S., Minunni, M., & Mascini, M. (2005). Analytical applications of aptamers. Biosensors and Bioelectronics, 20, 2424-2434. DOI: 10.1016/j.bios.2004.11.006.
93. Uzzo, R. G., Wei, J. T., Waldbaum, R. S., Perlmutter, A. P., Byrne, J. C., & Vaughan, D., (1995). The influence of prostate size on cancer detection. Urology, 46, 831-836. DOI: 10.1016/s0090-4295(99)80353-7.
94. Velonas, V. M., Woo, H. H., dos Remedios, C. G., & Assinder, S. J. (2013). Current status of biomarkers for prostate cancer. International Journal of Molecular Science s, 14, 11034-11060. DOI: 10.3390/ijms140611034.
95. Wang, X. Y., Zhou, J. M., Yun, W., Xiao, S. S., Chang, Z., He, P. G., & Fang, Y. Z. (2007). Detection of thrombin using electrogenerated c hemiluminescence based on Ru(bpy)2+ 3-doped silica nanoparticle aptasensor via target proteininduced strand displacement. Analytica Chimica Acta, 598, 242-248. DOI: 10.1016/j.aca.2007.07.050.
96. Wee, K. W., Kang, G. Y ., Park, J., Kang, J. Y., Yoon, D. S., Park, J. H., & Kim, T. S. (2005). Novel electrical detection of label-free disease marker proteins using piezoresistive selfsensing micro-cantilevers. Biosensors and Bioelectroni cs, 20, 1932-1938. DOI: 10.1016/j.bios.2004.09.023.
97. Weeks, B. L., Camarero, J., Noy, A., Miller, A. E., De Yoreo, J. J., & Stanker, L. (2003). A microcantileverbased pathogen detector. Scanning, 25, 297-299. DOI: 10.1002/sca.4950250605.
98. Wu C.L.,Yang X.J.,Tretiakova M.,Patton K.T.,Halpern E.F.,Woda B.A.,Young R.H.,Jiang Z., 2004, Analysis of ?-methylacyl-CoA racemase (P504S) expression in highgrade prostatic intraepitheli al neoplasia, Human Pathology, 35, 1008-1013,doi 10.1016/j.humpath.2004.03.019.
99. Willner, I., & Zayats, M. (2007). Electronic aptamer-based sensors. Angewandte Chemie International Edition, 46, 6408-6418. DOI: 10.1002/anie.200604524.
100. Xiao, Y., Lubin, A. A., Heeger, A. J., & Plaxco, K. W. (2005). Label-free electronic detection of thrombin in blood serum by using an aptamer-based sensor. Angewandte Chemie, 117, 5592-5595. DOI: 10.1002/ange.200500989.
101. Xu, D. K., Xu, D. W., Yu, X. B., Liu, Z. H., He,W., & Ma, Z. Q. (2005). Label-free electrochemical detection for aptamerbased ar ray electrodes. Analytical Chemistry, 77, 5107-5113. DOI: 10.1021/ac050192m.
102. Yang, D. K., Chen, C. S., & Chen, L. C. (2013). Screening of functional aptamers against ?-methylacyl-coA racemase. In Abstracts of the 13th American Institute of Chemical Engineers Annual Meeting, 3-8 November, 2013. San Francisco, CA, USA: American Institute of Chemical Engineers. Retrieved May 9, 2014, from https://aiche.confex.com/aiche/2013/webprogra m/Paper332288.html
103. Zani, A., Laschi, S., Mascini, M., & Marrazza, G. (2011). A new electrochemical multiplexed assay for PSA cancer marker detection. Electroanalysis, 23, 91-99. DOI: 10.1002/elan.2010004 86.
104. Zitzmann, S., Mier, W., Schad, A., Kinscherf, R., Askozylakis, V., Krämer, S., Altmann, A., Eisenhut, M., & Haberkorn, U. (2005). A new prostate carcinoma binding peptide (DUP-1) for tumor im aging and therapy. Clinical Cancer Research, 11, 139-146.